Ultima Genomics Validates ppmSeq Sensitivity in TRACERx MRD Data
Event summary
- Ultima Genomics presented TRACERx MRD data at AACR 2026, showcasing ppmSeq's low single-digit parts-per-million sensitivity for ctDNA detection.
- Collaborators LabCorp and DELFI Diagnostics presented additional data on ppmSeq's clinical implementation and performance.
- Ultima announced its inaugural global MRD Symposium, co-hosted with Dan Landau and Charles Swanton.
- TRACERx pilot study across 50 plasma samples achieved high analytical sensitivity without bespoke panel approaches.
- LabCorp's independent study showed ppmSeq's specificity exceeding 99.9% and limit of detection below 3 ppm.
The big picture
Ultima Genomics' ppmSeq technology is positioning itself as a new standard for ultrasensitive minimal residual disease (MRD) detection, challenging conventional bespoke panel approaches. The validation through TRACERx data and collaborations with major clinical and research institutions underscores its potential to transform cancer monitoring. The broader industry trend towards whole-genome sequencing for MRD detection is gaining momentum, with Ultima at the forefront of this shift.
What we're watching
- Clinical Adoption
- The pace at which ppmSeq transitions from research-grade to clinical-grade reliability will determine its market penetration.
- Competitive Positioning
- Whether Ultima can sustain its technological edge as competitors develop similar ultra-sensitive MRD detection methods.
- Regulatory Approval
- How quickly regulatory bodies endorse whole-genome MRD monitoring as a standard of care, impacting Ultima's commercialization strategy.
Related topics